SCHEDULE: Vanguard Group Reports Zero Stake in Eledon Pharmaceuticals

The Vanguard Group has reported a 0% beneficial ownership in Eledon Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Eledon Pharmaceuticals Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Eledon Pharmaceuticals Inc. common stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as largely neutral for Eledon Pharmaceuticals, as it primarily reflects a procedural change in how The Vanguard Group reports its beneficial ownership rather than a direct investment decision related to Eledon's performance.

Negatives

• The Vanguard Group, a significant institutional investor, no longer reports beneficial ownership in Eledon Pharmaceuticals Inc., effectively reducing its reported stake to 0%.
• While explained by an internal realignment, this change could be perceived negatively by some investors as a major fund group no longer directly holding shares under its primary reporting entity.

Risks

• Investor perception of a major institutional investor reporting a 0% stake, even if procedural, could lead to negative sentiment or scrutiny regarding Eledon Pharmaceuticals Inc.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Eledon Pharmaceuticals Inc.'s business or financial performance. It primarily details a change in beneficial ownership reporting by The Vanguard Group.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%."

Industry Context

StockSavvy.ai notes that such internal realignments are common among large asset managers like The Vanguard Group, often driven by operational efficiencies or regulatory interpretations. While this filing indicates a 0% reported stake by the parent entity, it does not necessarily mean a complete divestment by all Vanguard-managed funds, but rather a change in how beneficial ownership is aggregated and reported.

Comparison to Industry Standards

• This filing is a procedural update regarding beneficial ownership reporting and does not contain information directly comparable to industry performance standards for Eledon Pharmaceuticals Inc. The reporting change itself aligns with SEC guidelines for large institutional investors undergoing internal structural adjustments.

Stakeholder Impact

• Shareholders: May interpret the 0% reported stake by The Vanguard Group as a negative signal, even if it is a procedural change, potentially impacting market sentiment.
• Investment Professionals: Will need to track beneficial ownership from Vanguard's newly disaggregated subsidiaries separately to understand the full extent of Vanguard's holdings.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report their beneficial ownership separately in future filings.

Key Dates

Keywords

Eledon Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Adviser, Realignment